Tel: +44 (0)1223 316 855
life science research products, biological research products, biotechnology
close ...


Supplier:
Product types:
Request A Free TransIt-BrCa Sample
Active Endosome Escape Based Transfection Reagent

Highly effective & efficient in vitro delivery of Cas9 RNP for genome editing in challenging cells

Breast Cancer Cell-Optimised Transfection Reagent - TransIT®-BrCa

Breast Cancer Cell-Optimised Transfection Reagent - TransIT®-BrCa

Cambridge Bioscience offers a high performance, low toxicity DNA transfection reagent for breast cancer cell types. TransIT®-BrCa is the first reagent available that is wholly dedicated to cell line specific breast cancer lines, efficiently delivering DNA to many breast cancer cell types whilst maintaining low cellular toxicity levels and reduced experimental bias.

Benefits of Using TransIT®-BrCa
• Breast cancer cell optimised
• High expression levels in MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468 & T47D
• High efficiency
• Low cellular toxicity
• Cell density maintained
• Experimental bias reduced
• Superior transfection efficiency
• TransIT®-BrCa outperforms Lipofectamine® 2000 in multiple breast cancer cell lines
• Free samples available

Testimonial
"I set up a transfection of ZR-75-1 breast cancer cells (just GFP) to compare the results between our peptide, Lipofectamine 2000 and the Mirus Bio TransIT BrCa reagent. As is evident in my image, the TransIT BrCa reagent performed really well and I will be planning a large scale study in the near future."
Cian McCrudden, Research Fellow
School of Pharmacy, Queen's University, Belfast


TransIT®-BrCa Exhibits Higher Luciferase Expression in Breast Cancer Cells Compared to Other Transfection Reagents

TransIT-BrCa Luciferase Expression

Breast cancer cell lines, MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468 and T47D transfected with a luciferase expression plasmid using the designated reagents at the reagent-to-DNA ratios indicated beneath each bar. Transfections performed in 96-well plates using 0.1 µg of plasmid DNA per well. Luciferase expression measured at 24 hours post-transfection using a standard assay. Error bars represent standard deviation of triplicate wells.

TransIT®-BrCa Delivers Plasmid DNA With High Efficiency
TransIT-BrCa Plasmid DNA

TransIT®-BrCa used to transfect plasmid DNA encoding GFP into MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468 and T47D breast cancer cell lines. Transfections performed in 35 mm Mattek dishes using 4 µl of TransIT®-BrCa to deliver 2 µg of DNA (2:1 reagent:DNA ratio). Images captured at 48 hours post-transfection using a Zeiss Axiovert S100 inverted fluorescence microscope.

TransIT®-BrCa Yields High Efficiency Plasmid DNA Transfection

TransIT-BrCa Efficiency

TransIT®-BrCa used to transfect plasmid DNA encoding GFP into MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468 and T47D breast cancer cell lines. Transfections performed in 24-well plates using 1-1.5 µl of TransIT®-BrCa to deliver 0.5 µg of DNA (2:1 and 3:1, reagent:DNA ratio). Triplicate wells assayed 48 hours post-transfection on a Guava®  HT easyCyte flow cytometer.

Free Samples
Request a free TransIT®-BrCa sample Here

Material Available For Download
TransIT®-BrCa Protocol
TransIT®-BrCa Quick Reference Protocol
TransIT®-BrCa SDS
TransIT®-BrCa Optimisation Protocol on 12-well Plate

Lipofectamine® is a registered trademark of Life Technologies , Inc.
FuGENE is a registered trademark of Fugent, LLC, USA
Guava® is a registered trademark of MERCK KGAA

Products

Note: availability depends on country - see product detail page.

Doaa Mirus
Tonbo Biosciences